Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (August 2016)
25 slides from Adalta's investor presentation, August 2016
Slide 1: i-bodies – a new class of protein therapeutics to treat human disease
For personal use only i-bodies – a new class of protein therapeutics to treat human disease August 2016 Sam Cobb, CEO and Managing Director s.cobb@adalta.com.au
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: Corporate and investment summary
Corporate and investment summary For personal use only AdAlta: A drug discovery and development company focused on using its proprietary technology platform to generate a new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases Investment highlights Initial f
Slide 4: Corporate Snapshot
Corporate Snapshot: 22nd August For personal use only ASX CODE: 1AD Major Shareholders % Market Cap (at IPO price): $25M Yuuwa Capital LP 54.06 Cash: ~$11M HSBC Custody Nominees (Australia) Ltd 8.59 Shares on issue: 100,000,016 Citycastle Pty Ltd 5.31 Escrow: La Trobe University 3.04 Robin Beaumont
Slide 5: i-body technology
i-body technology Long loop that enables access to For personal use only AdAlta is developing a new technology platform that produces novel drug targets unique proteins known as i-bodies, that mimic the shape of shark antibody binding domain and engineers their key stability features into a human pr
Slide 6: i-body drug discovery and manufacture
i-body drug discovery and manufacture For personal use only Large diverse synthetic library of 2 billion i-body protein compounds that can bind to a broad range of therapeutically relevant targets i-body identified by i-body affinity matured Manufactured in microbial rapid screening to enhance targe
Slide 7: i-body technology advantages
i-body technology advantages For personal use only Challenging targets Multiple delivery routes Customised half-life Multi formatting Inhalation Ocular Oral-to-topical Because of the long binding The small physical size and As a result of their small size Can easily engineer unique loop of the i-bod
Slide 8: i-bodies combine benefits of small molecules and conventional antibodies
i-bodies combine benefits of small molecules and conventional antibodies For personal use only Long loop that Small Conventional AdAlta enables access to Molecule Antibody i-body novel drug targets High selectivity-specificity Low toxicity: no off target effects Cavity binding and new epitopes Stabi
Slide 9: i-body competitive differentiation
i-body competitive differentiation For personal use only Long loop Increased target diversity Derived from camel antibodies via immunisation Immunise mice to create human antibodies Short loop Animal Human Decreasing immunogenicity 9
Slide 10: Fibrosis: unmet medical need with multiple indications
Fibrosis: unmet medical need with multiple indications For personal use only Developing i-bodies as improved therapies for the treatment of fibrosis – a condition that is prevalent in 45-50% of all diseases Fibrosis can occur in many tissues of the body Lung Eye Liver as a result of inflammation or
Slide 11: AD-114 lead program in Idiopathic Pulmonary Fibrosis (IPF)
AD-114 lead program in Idiopathic Pulmonary Fibrosis (IPF) For personal use only AD-114 is lead i-body candidate in pre-clinical development – Demonstrates both anti-fibrotic and anti-inflammatory activity in the lung – Important for arresting and modifying the disease and tackling the treatment of
Slide 12: AD-114 prevents lung fibrosis in disease models
AD-114 prevents lung fibrosis in disease models For personal use only Extensive pre-clinical AD-114 studies have demonstrated positive in vitro (in the lab) and in vivo (in animals) data Normal IPF lung tissue IPF lung tissue + AD-114 lung tissue (lung disease mouse model) dosed for 21 days (lung di
Slide 13: AD-114 mechanism of action in idiopathic pulmonary fibrosis (IPF)
AD-114 mechanism of action in idiopathic pulmonary fibrosis (IPF) For personal use only CXCR4 expression increased in fast progressing IPF patient tissue AD-114 binds to the G protein-coupled receptor, CXCR4 (a chemokine receptor) CXCR4 has been demonstrated to play a central role in the development
Slide 14: AD-114 key advantages compared to existing IPF treatments
AD-114 key advantages compared to existing IPF treatments No effect Inhibits Inhibits For personal use only MIGRATION on normal slow IPF fast IPF fibroblasts progressors progressors i-body AD-114 ✔ ✔ ✔ Migration of normal & IPF patient Nintedanib (Boehringer) ✗ ✔ ✔ fibroblasts in vitro Pirfenidone (
Slide 15: AD-114 prevents eye fibrosis and has potential for broad application
Wet AMD (CNV mouse model) AD-114 prevents • Mouseeye fibrosis and has chorodial Contrac(on neovascularization model: single potential for broad Other fibrosis application indications: nanosecond laser burn to eye the For personal use only retina/RPE (0.5mJ) – Induces subretinal AD-114 reduces contra
Slide 16: Antibody market
Antibody market For personal use only 1986 2015 2020 60% 1 st Antibody- Sales from world top drugs are antibodies US$125bn Estimated antibody based drug US$81bn approved Antibody sales sales globally 50 Antibodies approved for a variety of diseases Multi-billion US$ market Source: mAbs (2016), 8:2,
Slide 17: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments Recent transactions confirm that big pharma are actively acquiring fibrosis assets at For personal use only an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-15 Adheron SDP051 Roche $
Slide 18: AdAlta business model – strategy to create value
AdAlta business model – strategy to create value For personal use only Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 19: Market benchmarks
Market benchmarks For personal use only Fibrosis PRM-151 exclusive license Sep-15 acquired by Roche Aug-15 by BMS Option to acquire Nov-14 by lead AD-114 $105m + $475m milestones $150m + $1.25b milestones BMS $444m milestones phase I asset phase IIa asset phase I asset Next gen Licence deal Sep-13 w
Slide 20: Strong intellectual property protection
Strong intellectual property protection For personal use only AdAlta has a strong portfolio of worldwide granted patents and applications that protect both the i-body technology platform and its i-body drug candidates Platform protection – AdAlta’s granted patents specifically cover a method of modi
Slide 21: AD-114 development: key milestones
AD-114 development: key milestones For personal use only CY2016 CY2017 CY2018 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Partnering of lead Manufacturing of lead candidate candidate based on other Toxicology studies benchmark deals Orphan designation Phase I Publication of data Other fibrosis indications BD and partne
Slide 22: Expected newsflow next months
Expected newsflow next 18 months For personal use only Q3 2016 Orphan Drug Designation (US FDA) Commence manufacturing of material for toxicology testing Presentation at Discovery on Target, Boston Q4 2016 Additional AD-114 IPF fibrosis data Hypertrophic scarring animal results for AD-114 Completion
Slide 23: Management and Board in place to deliver strategy
Management and Board in place to deliver strategy For personal use only Sam Cobb: Founding CEO and Director Dr John Chiplin: Independent Director Extensive experience in raising equity, contract and CEO of investment Company NewStar Ventures grant funding Managing Director of acquired antibody compa
Slide 24: Scientific Advisory Board
Scientific Advisory Board Internationally recognised with proven track record of drug development For personal use only David McGibney: pre-clinical and John Westwick: pulmonary drug clinical advisor discovery and development 20 years with Pfizer, including Head of Over 14 years experience at Novart
Slide 25: AdAlta investment summary
AdAlta investment summary For personal use only Powerful proprietary technology platform to develop a pipeline of i-bodies for the treatment of a wide range of human diseases Initial focus on treating Idiopathic Pulmonary Fibrosis and other fibrotic diseases - high unmet clinical need Advanced lead